Attention women! Removement injections threaten contraception and health!

Attention women! Removement injections threaten contraception and health!

England, Großbritannien - The British drug authority MHRA has published an urgent warning to popular weight losses such as Ozempic, Wegovy and Mounjaro. These drugs, which are often used to reduce weight, could affect the effectiveness of contraceptives and represent potential risks for unborn children. Women who use these preparations are particularly careful, especially with regard to their contraceptive methods, such as Kosmo

The MHRA has received over 40 reports on pregnancies from users of these medication, 26 of whom are connected to Mounjaro. Documented cases include birth errors, miscarriages and unwanted pregnancies despite contraception. The active ingredient tirepatide in Mounjaro, which is considered very potent, is particularly critical. The authority recommends women who take these medication to "double" their contraceptive methods and, in the event of a planned pregnancy, to prevent two months after breaking off the syringes.

risks and side effects

The use of Mounjaro can interfere with digestion and possibly lead to contraceptives from the body before their full effect. The MHRA has given specific recommendations that safe sex is particularly important, especially in the four weeks after the start of taking or after every dose increase. Dr. Alison Cave from the Mhra points out that the medication should not be used for aesthetic purposes and warns of the purchase of non -regulated sources.

In addition to the risks for women, these drugs could also endanger their children's health. Professor Rebecca Reynolds emphasizes that there is hardly any available data from human studies to ensure the safety of these weight loss resources during pregnancy. The National Pharmacists' Association of Great Britain calls for an urgent review and adjustment of regulations in this rapidly growing medication landscape.

action and treatment success

The weight loss injections, which also include Semaglutid, are now also approved in Germany against type 2 diabetes. An analysis of the risks and advantages of these GLP-1 receptor agonists shows that, among other things, they can reduce the risk of heart attack, stroke and dementia. In a recent study, it was found that the medication increases the feeling of satiety and extend the length of stay of the food in the digestive tract, which leads to weight loss. However, risks such as gastrointestinal problems and joint inflammation are also documented, such as pharmacies Umschau reported.

Treatment with these medication should be carried out under medical support and is usually scheduled for a period of one and a half years to be sustainable and prevent the yo-yo effect. However, the medicines are not intended for people who want to lose weight slightly because they fall under lifestyle medicines and the costs are not covered by health insurance companies.

In the current discussion, it is also pointed out that prominent reports of personalities such as Elon Musk and Kim Kardashian convey a distorted image of the actual suitability and use of these weight loss. The use should only be carried out under medical necessity and with careful monitoring, which is emphasized by the manufacturers like Novo Nordisk.

The risks mentioned and the complexity of the use of weight loss injections make it necessary for women and their doctors to discuss the potential consequences and the correct procedure when using these medication. A social and conscious handling of information is crucial to minimize misunderstandings and risks.